|
Post by Wallace907 on May 1, 2016 17:38:16 GMT
|
|
|
Post by Wallace907 on Nov 8, 2016 17:44:02 GMT
First earnings after approval. ACAD basically doubled modest, early sales projections. Currently up about 18% which is almost where it was prior to the drop it had during the criticized launch. It has about a half billion in funds. Very bright future ahead with the bigger indication being alzheimers.
|
|
|
Post by CM kipper007 on Sept 9, 2019 16:28:32 GMT
Are you still holding this??
|
|
|
Post by JHam on Sept 9, 2019 16:33:40 GMT
I've been following this today. Good news for shareholders and patients: www.businesswire.com/news/home/20190909005286/en/ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis- Pimavanserin achieved robust statistical superiority over placebo in time to relapse of dementia-related psychosis at planned interim efficacy analysis
- Pimavanserin has the potential to be the first FDA-approved drug for the treatment of dementia-related psychosis
- Approximately 1.2 million patients in the United States are diagnosed with dementia-related psychosis
- Conference call and webcast to be held today at 8:30 a.m. Eastern Time
|
|
|
Post by CM kipper007 on Sept 9, 2019 16:59:33 GMT
Any idea how many people were in the trial?
I am in meetings and not able to search right now.
This is amazing.
|
|